Organogenesis Reverse Merges with Avista Healthcare Public Acquisition Corp. (AHPAC)
Shots:
- With the closure of transaction Organogenesis- will be a public offering in NSE as "ORGO"
- The collaboration compromises of an initial enterprise value of ~$673mn- making Organogenesis to be wholly owned by AHPAC
- Avista Capital Partners agreed to invest $92mn in the collaboration of companies- further used in product portfolio and R&D
Ref: Organogenesis Inc. | Image: PRNewsWire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com